Avtor/Urednik		Antonič, J
Naslov		Tumorski označevalec CA 125 v ginekologiji
Prevedeni naslov		Tumour marker CA 125 in gynaecology
Tip		članek
Vir		Med Razgl
Vol. in št.		Letnik 32, št. 4
Leto izdaje		1993
Obseg		str. 613-20
Jezik		slo
Abstrakt		In spite of long term expectations of the dicovery of heart natriuretic substance only nine years ago the atrial natriuretic peptide was discovered. Some essential data about structure, synthesis, secretion and effects of othe peptide are given in the article. Two groups of the structuraly and functionaly different peptide's receptors are described. The importance of the receptor sites for the possible therapeutic usage is great. For the present the clinical importance of the atrial natriuretic peptide is limited to the evaluation of the peptide's plasma concentration as a prognostic factor. Therapeutic usage of the peptide in the pathological states with volume overload is in ecperimental phase. The tumor marker CA 125 was detected in the sera of patients with epithelial ovarian cancer using high levels of labelled monocional antibodies. The paper lists the tissues in which CA 125 was found both in normal conditions and during tumour degeneration. Body fluids which normally contain CA 125 are presented, as well as various factors responsible for elevated CA 125 levels in the serum, including physiological conditions, benign disorders and malignant diseases. The relationship between the tissue and serum CA 125 levels in the serum, including physiological conditions, benign disorders and malignant diseases. The relationship between the tissue and serum CA 125 levels is explained. Clinical application of serum CA 125 assay to gynaecologic diagnosis, disease monitoring and prognosis in ovarian cancer is described, as well as its potential use in patients with endometrial cancer and endometriosis. Finally, different CA 125 assays are presented, as well as the limitations of these methods.
Deskriptorji		OVARIAN NEOPLASMS ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE